Syndecan‐4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes. Issue 9 (18th February 2016)

• Record Type: Journal Article
• Authors: Das, Subhamoy; Monteforte, Anthony J.; Singh, Gunjan; Majid, Marjan; Sherman, Michael B.; Dunn, Andrew K.; Baker, Aaron B.
• Is Part Of: Advanced healthcare materials. Volume 5:Issue 9(2016)
• Page Start: 1008
• Page End: 1013
• Publication Date: 2016-02-18
• Subjects: fibroblast growth factor‐2 (FGF‐2) -- ischemia -- peripheral vascular diseases -- syndecan‐4 -- therapeutic angiogenesis; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.201500993
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract : Delivering syndecan‐4 with FGF‐2 improves the effectiveness of FGF‐2 therapy for ischemia in the diabetic disease state. The syndecan‐4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan‐4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.